SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (1966)5/7/1998 9:30:00 AM
From: sds  Read Replies (2) | Respond to of 4676
 
David, I disagree.

While the spike in ENMD was definitely abetted by general media attention, the fact is that they got results in the mouse/rat model. ISIP's cancer drugs have never shown that level of effectiveness in in any animal model.

I stand by my statement -- ISIP won't spike like that. Their cancer drugs are not blockbusters, and their other possible indications (RA, Crohns, psoriasis, etc.) are not big enough to cause that kind of spike.

sds


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News